IRLAB Therapeutics: IRLAB Obtains Regulatory Approval to Conduct Phase IIb Study With Pirepemat - One Step Closer To Improving Balance and Reducing Fall Injuries For People Living With Parkinson's Disease

GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)IRLAB (Nasdaq Stockholm: IRLAB A) IRLAB receives regulatory approval from the Swedish MPA for conducting

Related Keywords

Sweden ,Stockholm ,Poland ,Spain ,Gothenburg ,Vastra Gotalands Lan ,Polish ,Spanish ,Swedish ,Viktor Siewertz ,Joakim Tedroff ,Clinical Research Organization ,Ir Corporate Communications ,Nasdaq Stockholm ,Voluntary Harmonization Procedure ,Nicholas Waters ,Integrative Screening Process ,Nasdaq Stockholm Main ,Noirlab ,Herapeutics ,Btains ,Egulatory ,Approval ,Conduct ,Hase ,Study ,Ith ,Irepemat ,Step ,Loser ,Improving ,Balance ,Educing ,Wall ,Injuries ,People ,Diving ,Parkinson ,Disease ,